Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 479

1.

Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.

Tiwari-Heckler S, Gan-Schreier H, Stremmel W, Chamulitrat W, Pathil A.

Nutrients. 2018 May 21;10(5). pii: E649. doi: 10.3390/nu10050649.

2.

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.

Guzman CB, Duvvuru S, Akkari A, Bhatnagar P, Battioui C, Foster W, Zhang XM, Shankar SS, Deeg MA, Chalasani N, Hardy TA, Kazda CM, Pillai SG.

Hepatol Commun. 2018 Mar 23;2(5):561-570. doi: 10.1002/hep4.1171. eCollection 2018 May.

3.

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity.

Pirola CJ, Sookoian S.

World J Gastroenterol. 2018 Apr 21;24(15):1601-1615. doi: 10.3748/wjg.v24.i15.1601. Review.

4.

NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Soti S, Corey KE, Lake JE, Erlandson KM.

Curr HIV/AIDS Rep. 2018 Jun;15(3):212-222. doi: 10.1007/s11904-018-0392-1. Review.

PMID:
29671204
5.

NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.

Sliz E, Sebert S, Würtz P, Kangas AJ, Soininen P, Lehtimäki T, Kähönen M, Viikari J, Männikkö M, Ala-Korpela M, Raitakari OT, Kettunen J.

Hum Mol Genet. 2018 Jun 15;27(12):2214-2223. doi: 10.1093/hmg/ddy124.

6.

Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes.

Mahajan A, Wessel J, Willems SM, Zhao W, Robertson NR, Chu AY, Gan W, Kitajima H, Taliun D, Rayner NW, Guo X, Lu Y, Li M, Jensen RA, Hu Y, Huo S, Lohman KK, Zhang W, Cook JP, Prins BP, Flannick J, Grarup N, Trubetskoy VV, Kravic J, Kim YJ, Rybin DV, Yaghootkar H, Müller-Nurasyid M, Meidtner K, Li-Gao R, Varga TV, Marten J, Li J, Smith AV, An P, Ligthart S, Gustafsson S, Malerba G, Demirkan A, Tajes JF, Steinthorsdottir V, Wuttke M, Lecoeur C, Preuss M, Bielak LF, Graff M, Highland HM, Justice AE, Liu DJ, Marouli E, Peloso GM, Warren HR; ExomeBP Consortium; MAGIC Consortium; GIANT Consortium, Afaq S, Afzal S, Ahlqvist E, Almgren P, Amin N, Bang LB, Bertoni AG, Bombieri C, Bork-Jensen J, Brandslund I, Brody JA, Burtt NP, Canouil M, Chen YI, Cho YS, Christensen C, Eastwood SV, Eckardt KU, Fischer K, Gambaro G, Giedraitis V, Grove ML, de Haan HG, Hackinger S, Hai Y, Han S, Tybjærg-Hansen A, Hivert MF, Isomaa B, Jäger S, Jørgensen ME, Jørgensen T, Käräjämäki A, Kim BJ, Kim SS, Koistinen HA, Kovacs P, Kriebel J, Kronenberg F, Läll K, Lange LA, Lee JJ, Lehne B, Li H, Lin KH, Linneberg A, Liu CT, Liu J, Loh M, Mägi R, Mamakou V, McKean-Cowdin R, Nadkarni G, Neville M, Nielsen SF, Ntalla I, Peyser PA, Rathmann W, Rice K, Rich SS, Rode L, Rolandsson O, Schönherr S, Selvin E, Small KS, Stančáková A, Surendran P, Taylor KD, Teslovich TM, Thorand B, Thorleifsson G, Tin A, Tönjes A, Varbo A, Witte DR, Wood AR, Yajnik P, Yao J, Yengo L, Young R, Amouyel P, Boeing H, Boerwinkle E, Bottinger EP, Chowdhury R, Collins FS, Dedoussis G, Dehghan A, Deloukas P, Ferrario MM, Ferrières J, Florez JC, Frossard P, Gudnason V, Harris TB, Heckbert SR, Howson JMM, Ingelsson M, Kathiresan S, Kee F, Kuusisto J, Langenberg C, Launer LJ, Lindgren CM, Männistö S, Meitinger T, Melander O, Mohlke KL, Moitry M, Morris AD, Murray AD, de Mutsert R, Orho-Melander M, Owen KR, Perola M, Peters A, Province MA, Rasheed A, Ridker PM, Rivadineira F, Rosendaal FR, Rosengren AH, Salomaa V, Sheu WH, Sladek R, Smith BH, Strauch K, Uitterlinden AG, Varma R, Willer CJ, Blüher M, Butterworth AS, Chambers JC, Chasman DI, Danesh J, van Duijn C, Dupuis J, Franco OH, Franks PW, Froguel P, Grallert H, Groop L, Han BG, Hansen T, Hattersley AT, Hayward C, Ingelsson E, Kardia SLR, Karpe F, Kooner JS, Köttgen A, Kuulasmaa K, Laakso M, Lin X, Lind L, Liu Y, Loos RJF, Marchini J, Metspalu A, Mook-Kanamori D, Nordestgaard BG, Palmer CNA, Pankow JS, Pedersen O, Psaty BM, Rauramaa R, Sattar N, Schulze MB, Soranzo N, Spector TD, Stefansson K, Stumvoll M, Thorsteinsdottir U, Tuomi T, Tuomilehto J, Wareham NJ, Wilson JG, Zeggini E, Scott RA, Barroso I, Frayling TM, Goodarzi MO, Meigs JB, Boehnke M, Saleheen D, Morris AP, Rotter JI, McCarthy MI.

Nat Genet. 2018 Apr;50(4):559-571. doi: 10.1038/s41588-018-0084-1. Epub 2018 Apr 9.

PMID:
29632382
7.

High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease.

Tepper CG, Dang JHT, Stewart SL, Fang DM, Wong KA, Liu SY, Davis RR, Dao DY, Gregg JP, Török NJ, Chen MS Jr.

Cancer. 2018 Apr 1;124 Suppl 7:1583-1589. doi: 10.1002/cncr.31122.

PMID:
29578593
8.

Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease.

Sookoian S, Flichman D, Garaycoechea ME, Gazzi C, Martino JS, Castaño GO, Pirola CJ.

Sci Rep. 2018 Mar 23;8(1):5097. doi: 10.1038/s41598-018-23453-9.

9.

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).

Del Campo JA, Gallego-Durán R, Gallego P, Grande L.

Int J Mol Sci. 2018 Mar 19;19(3). pii: E911. doi: 10.3390/ijms19030911. Review.

10.

Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.

Mitsche MA, Hobbs HH, Cohen JC.

J Biol Chem. 2018 May 4;293(18):6958-6968. doi: 10.1074/jbc.RA118.002333. Epub 2018 Mar 19. Erratum in: J Biol Chem. 2018 Jun 15;293(24):9232.

11.

Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.

Mancini M, Summers P, Faita F, Brunetto MR, Callea F, De Nicola A, Di Lascio N, Farinati F, Gastaldelli A, Gridelli B, Mirabelli P, Neri E, Salvadori PA, Rebelos E, Tiribelli C, Valenti L, Salvatore M, Bonino F.

World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231. Review.

12.

Managing the Burden of Non-NASH NAFLD.

Danford CJ, Sanchez JE, Corey KE.

Curr Hepatol Rep. 2017 Dec;16(4):326-334. doi: 10.1007/s11901-017-0371-9. Epub 2017 Oct 27.

PMID:
29503789
13.

The role of NAFLD in cardiometabolic disease: an update.

Faasse S, Braun H, Vos M.

F1000Res. 2018 Feb 9;7:170. doi: 10.12688/f1000research.12028.1. eCollection 2018. Review.

14.

Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.

Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, Arca M.

Sci Rep. 2018 Feb 27;8(1):3702. doi: 10.1038/s41598-018-21939-0.

15.

Hispanic health in the USA: a scoping review of the literature.

Velasco-Mondragon E, Jimenez A, Palladino-Davis AG, Davis D, Escamilla-Cejudo JA.

Public Health Rev. 2016 Dec 7;37:31. doi: 10.1186/s40985-016-0043-2. eCollection 2016. Review.

16.

Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.

Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A.

Redox Biol. 2018 May;15:467-479. doi: 10.1016/j.redox.2018.01.009. Epub 2018 Feb 3. Review.

17.

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S.

Hepatol Commun. 2017 Nov 30;2(1):48-57. doi: 10.1002/hep4.1124. eCollection 2018 Jan.

18.

Interaction between the patatin-like phospholipase domain-containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis.

Liangpunsakul S, Beaudoin JJ, Shah VH, Puri P, Sanyal AJ, Kamath PS, Lourens SG, Tang Q, Katz BP, Crabb DW, Chalasani NP.

Hepatol Commun. 2017 Nov 11;2(1):29-34. doi: 10.1002/hep4.1123. eCollection 2018 Jan.

19.

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.

Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y, Tanaka S, Sumida Y, Yasui K, Takahashi M, Matsuo K, Itoh Y, Tokushige K, Hashimoto E, Kiyosawa K, Kawaguchi M, Itoh H, Uto H, Komorizono Y, Shirabe K, Takami S, Takamura T, Kawanaka M, Yamada R, Matsuda F, Okanoue T.

PLoS One. 2018 Jan 31;13(1):e0185490. doi: 10.1371/journal.pone.0185490. eCollection 2018.

20.

Interactions between Genetics and Sugar-Sweetened Beverage Consumption on Health Outcomes: A Review of Gene-Diet Interaction Studies.

Haslam DE, McKeown NM, Herman MA, Lichtenstein AH, Dashti HS.

Front Endocrinol (Lausanne). 2018 Jan 8;8:368. doi: 10.3389/fendo.2017.00368. eCollection 2017. Review.

Supplemental Content

Support Center